¼¼°èÀÇ ÁøÅëÁ¦ ½ÃÀå
Analgesics
»óǰÄÚµå : 1766893
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 578 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,222,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,666,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

ÁøÅëÁ¦ ¼¼°è ½ÃÀåÀº 2030³â±îÁö 728¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 535¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ÁøÅëÁ¦ ¼¼°è ½ÃÀåÀº 2024³âºÎÅÍ 2030³â±îÁö CAGR 5.3%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 728¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀΠ󹿾àÀº CAGR 5.0%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 438¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. OTC ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 5.8%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 172¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 7.1%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ÁøÅëÁ¦ ½ÃÀåÀº 2024³â¿¡ 172¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 108¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 7.1%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 3.8%¿Í 4.2%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 4.1%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ÁøÅëÁ¦ ½ÃÀå µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

ÀϹÝÀûÀ¸·Î ÁøÅëÁ¦·Î ¾Ë·ÁÁø ÁøÅëÁ¦´Â ÅëÁõÀ» ¿ÏÈ­Çϱâ À§ÇØ »ç¿ëµÇ´Â ´Ù¾çÇÑ ¾à¹°±ºÀÔ´Ï´Ù. ÁøÅëÁ¦´Â ³úÀÇ ÅëÁõ ½ÅÈ£¸¦ Â÷´ÜÇϰųª ³ú°¡ ÀÌ ½ÅÈ£¸¦ ÇØ¼®ÇÏ´Â °ÍÀ» ¹æÇØÇÔÀ¸·Î½á È¿°ú¸¦ ¹ßÈÖÇÕ´Ï´Ù. ÁøÅëÁ¦´Â ¿©·¯ Á¾·ù°¡ ÀÖÀ¸¸ç, °¢°¢ ÅëÁõÀÇ Á¾·ù¿Í Á¤µµ¿¡ µû¶ó ÀûÇÕÇÑ ÁøÅëÁ¦°¡ ÀÖ½À´Ï´Ù. °¡Àå Àß ¾Ë·ÁÁø °ÍÀº À̺ÎÇÁ·ÎÆæÀ̳ª ¾Æ½ºÇǸ°°ú °°Àº ºñ½ºÅ×·ÎÀ̵强 Ç׿°ÁõÁ¦(NSAIDs)·Î, ¿°ÁõÀ» ¾ïÁ¦ÇÏ°í °æÁõ¿¡¼­ ÁߵÀÇ ÅëÁõ¿¡ È¿°úÀûÀÔ´Ï´Ù. ¸ð¸£ÇÉÀ̳ª ¿Á½ÃÄÚµ·°ú °°Àº ¿ÀÇÇ¿ÀÀ̵å´Â ´õ °­ÇÑ ÁøÅëÁ¦·Î¼­ ½ÉÇÑ ÅëÁõ¿¡ ó¹æµÇ´Â °æ¿ì°¡ ¸¹Áö¸¸, ÀÇÁ¸¼ºÀ̳ª Áßµ¶ÀÇ À§ÇèÀÌ ÀÖ½À´Ï´Ù. ¶Ç ´Ù¸¥ ¹üÁÖ´Â ¾Æ¼¼Æ®¾Æ¹Ì³ëÆæ(ÆÄ¶ó¼¼Å¸¸ô)À¸·Î, °æÁõ¿¡¼­ ÁߵÀÇ ÁøÅë°ú ÇØ¿­¿¡ ³Î¸® »ç¿ëµÇ¸ç ÀϹÝÀǾàǰ¿¡µµ ¸¹ÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù.

ÁøÅëÁ¦ÀÇ »ç¿ëÀº ÀÇÇÐ ¿¬±¸ÀÇ ¹ßÀü°ú ÅëÁõÀÇ ¸ÞÄ¿´ÏÁò¿¡ ´ëÇÑ ÀÌÇØ°¡ ±í¾îÁü¿¡ µû¶ó ÇØ¸¶´Ù Å©°Ô ¹ßÀüÇϰí ÀÖ½À´Ï´Ù. ¼­¹æÇü Á¤Á¦, °æÇÇÈí¼ö ÆÐÄ¡¿Í °°Àº »õ·Î¿î Á¦Çü°ú Åõ¿© ¹æ¹ýÀ¸·Î ÅëÁõ °ü¸®ÀÇ È¿°ú¿Í ÆíÀǼºÀÌ Çâ»óµÇ¾ú½À´Ï´Ù. ¶ÇÇÑ, ÇÑ ¹øÀÇ Åõ¿©·Î ¿©·¯ ÁøÅëÁ¦¸¦ ÅëÇÕÇÑ º¹ÇÕÁ¦ÀÇ °³¹ß·Î ¼­·Î ´Ù¸¥ ÅëÁõ °æ·Î¸¦ µ¿½Ã¿¡ Ç¥ÀûÈ­ÇÏ¿© ÅëÁõ ¿ÏÈ­ È¿°ú¸¦ Çâ»ó½ÃÄ×½À´Ï´Ù. ±×·¯³ª ¿ÀÇÇ¿ÀÀ̵带 Áß½ÉÀ¸·Î ÇÑ ÁøÅëÁ¦ÀÇ ±¤¹üÀ§ÇÑ »ç¿ëÀº ³ôÀº Áßµ¶ ¹× °ú´Ùº¹¿ë·üÀ» Ư¡À¸·Î ÇÏ´Â ¿ÀÇÇ¿ÀÀ̵å À§±â µî ½É°¢ÇÑ °øÁߺ¸°Ç ¹®Á¦¸¦ ¾ß±âÇϰí ÀÖ½À´Ï´Ù. ÀÌ¿¡ µû¶ó À§Àå ºÎÀÛ¿ëÀÌ ÀûÀº »õ·Î¿î ºñ½ºÅ×·ÎÀ̵强 Ç׿°ÁõÁ¦ °³¹ß, ºñ¾à¹° ¿ä¹ý ¿¬±¸ Ȱ¼ºÈ­ µî º¸´Ù ¾ÈÀüÇϰí ÀÇÁ¸¼ºÀÌ ¾ø´Â ÁøÅë ¹æ¹ýÀ» ã´Â ¹æÇâÀ¸·Î ÀüȯµÇ°í ÀÖ½À´Ï´Ù.

ÁøÅëÁ¦ ½ÃÀåÀÇ ¼ºÀåÀº ¿©·¯ °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ¾à¹°Àü´Þ ½Ã½ºÅÛÀÇ ¹ßÀüÀ¸·Î ÁøÅëÁ¦°¡ º¸´Ù È¿°úÀûÀÌ°í »ç¿ëÀÚ Ä£È­ÀûÀÎ ÁøÅëÁ¦¸¦ ¸¸µé ¼ö ÀÖ°Ô µÇ¾ú°í, ȯÀÚ Á¦¾îÇü ÁøÅëÁ¦ ÆßÇÁ¿Í ¿þ¾î·¯ºí ¾à¹°Àü´Þ ±â±â¿Í °°Àº Çõ½ÅÀÌ Àα⸦ ¾ò°í ÀÖ½À´Ï´Ù. °üÀý¿°, ¾Ï µî Àå±âÀûÀÎ ÅëÁõ °ü¸®°¡ ÇÊ¿äÇÑ ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡µµ ÁøÅëÁ¦¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, °í·ÉÈ­ »çȸ·Î Á¢¾îµé¸é¼­ ³ëÀεéÀÌ ¸¸¼º ÅëÁõ ÁúȯÀ» °ÞÀ» °¡´É¼ºÀÌ ³ô¾ÆÁü¿¡ µû¶ó ÁøÅëÁ¦ ¼Òºñ°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¼ÒºñÀÚ Çൿ Æ®·»µå¿¡¼­´Â ºü¸¥ ÅëÁõ ¿ÏÈ­¸¦ À§ÇØ ½ÃÆÇµÇ´Â ÁøÅëÁ¦¸¦ ¼±È£ÇÏ´Â °æÇâÀÌ °­È­µÇ°í ÀÖÀ¸¸ç, ÀÌ´Â ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ½ÅÈï±¹ ½ÃÀåÀÇ ÀÇ·áºñ ÁöÃâ Áõ°¡¿Í ÀÇ·á Á¢±Ù¼º Çâ»óÀ¸·Î ½ÃÀå Àúº¯ÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. Á¦¾à»çµéµµ ±âÁ¸ ÁøÅëÁ¦¸¦ ´ëüÇÒ ¼ö ÀÖ´Â ¾ÈÀüÇÑ ÁøÅëÁ¦¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ´ëÀÀÇÏ¿© º¸´Ù ¿ì¼öÇÑ ¾ÈÀü¼º°ú È¿´ÉÀ» °¡Áø »õ·Î¿î ÁøÅëÁ¦¸¦ °³¹ßÇϱâ À§ÇØ ¿¬±¸°³¹ß¿¡ ¸¹Àº ÅõÀÚ¸¦ Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀÌ ÁøÅëÁ¦ ½ÃÀåÀÇ ¿ªµ¿ÀûÀ̰í È®ÀåÀûÀΠƯ¼ºÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

¾à¹° À¯Çü(󹿾à, OTC), ¾à¹° Á¾·ù(¿ÀÇÇ¿ÀÀ̵å, NSAIDs, ±âŸ ¾à¹° Á¾·ù), Åõ¿© °æ·Î(°æ±¸, ºñ°æ±¸, ±¹¼Ò, °æÇÇ, Á÷Àå)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

¿ì¸®´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM ¹× ¾÷°è °íÀ¯ÀÇ SLMÀ» Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Analgesics Market to Reach US$72.8 Billion by 2030

The global market for Analgesics estimated at US$53.5 Billion in the year 2024, is expected to reach US$72.8 Billion by 2030, growing at a CAGR of 5.3% over the analysis period 2024-2030. Prescription, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$43.8 Billion by the end of the analysis period. Growth in the OTC segment is estimated at 5.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$17.2 Billion While China is Forecast to Grow at 7.1% CAGR

The Analgesics market in the U.S. is estimated at US$17.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$10.8 Billion by the year 2030 trailing a CAGR of 7.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.8% and 4.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR.

Global Analgesics Market - Key Trends & Drivers Summarized

Analgesics, commonly known as painkillers, are a diverse group of drugs used to relieve pain. They work by blocking pain signals in the brain or by interfering with the brain's interpretation of these signals. There are several types of analgesics, each suited to different types and severities of pain. The most well-known categories include nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and aspirin, which reduce inflammation and are effective for mild to moderate pain. Opioids like morphine and oxycodone are stronger analgesics, often prescribed for severe pain but come with a risk of dependency and addiction. Another category is acetaminophen (paracetamol), which is widely used for mild to moderate pain relief and fever reduction, often included in over-the-counter medications.

The use of analgesics has evolved significantly over the years, driven by advances in medical research and an increasing understanding of pain mechanisms. New formulations and delivery methods, such as extended-release tablets and transdermal patches, have improved the efficacy and convenience of pain management. Additionally, the development of combination drugs that incorporate multiple analgesics into a single dose has enhanced pain relief outcomes by targeting different pain pathways simultaneously. However, the widespread use of analgesics, particularly opioids, has led to significant public health challenges, including the opioid crisis, characterized by high rates of addiction and overdose. This has prompted a shift towards finding safer, non-addictive pain relief options, such as the development of new NSAIDs with fewer gastrointestinal side effects and increased research into non-pharmacological therapies.

The growth in the analgesics market is driven by several factors. Advancements in drug delivery systems have made analgesics more effective and user-friendly, with innovations like patient-controlled analgesia pumps and wearable drug delivery devices gaining popularity. The rising prevalence of chronic diseases such as arthritis and cancer, which often require long-term pain management, has also fueled demand for analgesics. Additionally, an aging global population is contributing to increased consumption of these medications, as older adults are more likely to experience chronic pain conditions. Consumer behavior trends show a growing preference for over-the-counter analgesics for quick and accessible pain relief, further boosting market growth. Moreover, increased healthcare spending and greater access to medical care in developing regions are expanding the market's reach. Pharmaceutical companies are also investing heavily in research and development to create new analgesics with better safety profiles and effectiveness, responding to the growing demand for safer alternatives to traditional painkillers. These factors collectively underscore the dynamic and expanding nature of the analgesics market.

SCOPE OF STUDY:

The report analyzes the Analgesics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Type (Prescription, OTC); Drug Class (Opioids, NSAIDs, Other Drug Classes); Route of Administration (Oral, Parenteral, Topical, Transdermal, Rectal)

Geographic Regions/Countries:

World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Spain; Russia; Rest of Europe; Asia-Pacific; Australia; India; South Korea; Rest of Asia-Pacific; Latin America; Argentina; Brazil; Mexico; Rest of Latin America; Middle East; Iran; Israel; Saudi Arabia; UAE; Rest of Middle East; Africa.

Select Competitors (Total 146 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â